• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

    11/2/21 4:05:00 PM ET
    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REPH alert in real time by email

    SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights.

    To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 4546348. Those interested in listening to the conference call live via webcast may do so by visiting the "Events" page in the Investor section of the Company's website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

    About Recro

    Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

    In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients' pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

    For more information about Recro's CDMO solutions, visit recrocdmo.com.



    Contacts:
    Stephanie Diaz (Investors)
    Vida Strategic Partners
    415-675-7401
    [email protected] 
    
    Tim Brons (Media)
    Vida Strategic Partners
    415-675-7402
    [email protected] 
    
    Ryan D. Lake (CFO)
    Recro
    770-531-8365
    [email protected]

    Primary Logo

    Get the next $REPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPH

    DatePrice TargetRatingAnalyst
    10/12/2021Outperform
    William Blair
    More analyst ratings

    $REPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      2/6/24 5:31:29 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 6:00:30 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      1/26/24 5:59:39 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

      With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

      3/21/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Fourth Quarter and Year End 2021 Financial Results

      Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

      3/1/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

      SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

      2/23/22 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 3:53:17 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)

      SC 13G/A - Societal CDMO, Inc. (0001588972) (Subject)

      2/14/24 2:27:06 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Recro Pharma Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      8/31/23 11:59:02 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    SEC Filings

    See more
    • Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/28/23 4:14:11 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Recro Pharma Inc.

      10-Q - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:13:18 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Societal CDMO, Inc. (0001588972) (Filer)

      11/8/23 4:11:37 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Financials

    Live finance-specific insights

    See more
    • Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

      SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

      2/22/22 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro Reports Third Quarter 2021 Financial Results

      Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

      11/9/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

      SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro

      11/2/21 4:05:00 PM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Recro Pharma

      William Blair initiated coverage of Recro Pharma with a rating of Outperform

      10/12/21 7:16:48 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Recro Announces Executive Changes

      MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

      12/16/20 7:00:00 AM ET
      $REPH
      Biotechnology: Pharmaceutical Preparations
      Health Care